We’re attending Biotechnology Innovation Organization’s #BIO2024 conference! Anne-Virginie Eggimann, our Chief Regulatory Officer, will be speaking on a panel discussing the latest guidance in platform product innovation. Mark your calendars and register now: https://lnkd.in/eBVwb3gh
Tessera Therapeutics
Biotechnology Research
Somerville, MA 31,649 followers
We are pioneering Gene Writing (TM) beyond its current limitations.
About us
Our Gene Writing™ technology advances genetic medicine beyond its current limitations. Learn more at http://TesseraTherapeutics.com
- Website
-
http://tesseratx.com
External link for Tessera Therapeutics
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Somerville, MA
- Type
- Privately Held
Locations
-
Primary
Get directions
Somerville, MA 02143, US
Employees at Tessera Therapeutics
Updates
-
At #ASGCT2024, our CEO, Michael Severino, was featured on an episode of BiotechTV diving deeper into the remaining unmet need for patients with #SickleCellDisease and the rapid progress of our in vivo rewriting therapies toward the clinic. Watch the full episode for our latest advancements across our #GeneWriting and delivery platforms.
𝐀𝐒𝐆𝐂𝐓 𝟐𝟎𝟐𝟒: In humanized mouse models, Tessera Therapeutics is demonstrating LNP delivery of gene writers to, and rewriting of, hematopoietic stem cells to an extent that could be curative in sickle cell disease. CEO Michael Severino describes the sickle cell data Tessera is presenting at #ASGCT2024, and highlights the company's gene writing platform and programs more broadly. Full video: https://lnkd.in/gh2C4Wy2 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
May is #AAPI Heritage Month! The 2024 theme is “Advancing Leaders Through Innovation”, focused on expanding leadership opportunities for the AAPI community. Join us in celebrating the contributions of Asian Americans and Pacific Islanders in driving innovations in #GeneticMedicine and beyond.
-
-
We're honored to be included in this #FlagshipFounded recap list of companies who presented at #ASGCT2024 as we continue to write the #FutureofGeneticMedicine! Check out the full summary to learn more about our new preclinical data highlighting advancements across our platforms.
Flagship-founded companies joined other leaders in #cellandgenetherapy at the American Society of Gene & Cell Therapy's Annual Meeting, sharing strides in the development of their respective bioplatform technologies and progress toward potentially transformative medicines. Read the full summary and highlights below: https://lnkd.in/emmmbgbN 🔷 Ring Therapeutics shared data in nonhuman primates showing the ability to redose genetic medicines using their vectors based on a little-known class of viruses called anelloviruses. 🔷 Tessera Therapeutics displayed curative results in humanized mouse models using its Gene Writers and proprietary lipid nanoparticles to restore normal hemoglobin production in hematopoietic stem cells in the bone marrow without chemotherapy or mobilization for the treatment of #sicklecelldisease. 🔷 Alltrna demonstrated robust ability to readthrough premature stop codons in mouse models, promising preclinical results that suggest their engineered tRNAs could offer a versatile approach to rescue protein production in rare and ulta-rare diseases caused by nonsense mutations, known as stop codon disease. 🔷 Omega Therapeutics showed preclinical data highlighting their ability to program epigenetic controllers to upregulate gene expression for a variety of genes types and cell conditions, providing effects that last weeks to months after a single dose. 🔷 Sana Biotechnology, Inc. displayed data showing a promising safety profile for their in vivo CAR T therapy, suggesting its potential to offer comparable efficacy and genomic safety as established treatments.
-
Thank you to the American Association of Pharmaceutical Scientists (AAPS) | @aapscomms for providing Hari Pujar, our COO, with the opportunity to lead the opening plenary session at #NBC2024 on next-generation approaches to #biotechnology modality development! We're excited to be part of this year’s National Biotechnology Conference as we pioneer the #FutureofGeneticMedicine.
👋 Welcome to the first day of the National Biotechnology Conference, #NBC2024! Join us for the Opening Plenary in just a few hours that features Hari Pujar, Ph.D., of Tessera Therapeutics, discussing his company's advancements in #genome engineering. Register now!
NBC 2024 Starts Today!
aaps.org
-
We're proud to share highlights of the advances we've made in our #GeneWriting and delivery platforms at #ASGCT2024. Read our press release to learn more here: https://lnkd.in/exxk3Du6
-
-
We’re thrilled to present six new data abstracts at this year's American Society of Gene & Cell Therapy annual meeting! Stop by our oral and poster presentations to catch up on our progress across our #GeneWriting and delivery platforms. Check out the details and mark your calendars: https://lnkd.in/e6cFpzyx #ASGCT2024
-
We celebrate diversity and inclusion on #TeamTessera. Ivy Pin-Fang Chen, Regulatory Strategy Manager, shares how Tessera’s welcoming culture encourages teammates to showcase their unique talents. Our differences make us stronger and fuel our shared goal of pioneering the #FutureofGeneticMedicine.
-
Tessera Therapeutics reposted this
We look forward to showcasing multiple new datasets at the American Society of Gene & Cell Therapy Annual Meeting, including our progress towards in vivo therapies for phenylketonuria, alpha-1 antitrypsin deficiency, sickle cell disease and Wilson's disease, as well as our advancements in novel T-cell based therapies. Learn more about our presentations here: https://lnkd.in/e6cFpzyx #ASGCT2024
-
-
Happy #NationalDNADay! The human genome holds immense potential to generate powerful insights and innovations. Building on the discovery of the double helix, our mission is to cure disease by writing in the code of life.
-